Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for carfilzomib (compound)
Most Correlated Studies
- Multiple myeloma LP-1 cells resistant to proteasome inhibitor carfilzomib
- Multiple myeloma KMS-11 and KMS-34 cells resistant to 12nM carfilzomib
- L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
- L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
- L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
Most Relevant Literature
- Acute suppression of translation by hyperthermia enhances anti-myeloma activity of carfilzomib.
- Carfilzomib-Loaded Ternary Polypeptide Nanoparticles Stabilized by Polycationic Complexation.
- Implications and hidden toxicity of cardiometabolic syndrome and early-stage heart failure in carfil…
- Antibody-Mediated Nanodrug of Proteasome Inhibitor Carfilzomib Boosts the Treatment of Multiple Myel…
- Genome-wide analysis in PC6 electroacupuncture to ameliorate carfilzomib-induced cardiotoxicity in m…
Most Relevant Clinical Trials
- Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
- B-Cell Targeted Carfilzomib Desensitization
- Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children
- Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM
- Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Car…
